Working Paper Article Version 1 This version is not peer-reviewed

Bringing Onco-innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine

Version 1 : Received: 17 August 2020 / Approved: 18 August 2020 / Online: 18 August 2020 (16:30:04 CEST)

How to cite: Horgan, D.; Ciliberto, G.; Conte, P.; Curigliano, G.; Seijo, L.; M. Montuenga, L.; Garassino, M.; Penault-Llorca, F.; Galli, F.; Ray-Coquard, I.; Querleu, D.; Riegman, P.; Kerr, K.; Van Poppel, H.; Bjartell, A.; Codacci-Pisanelli, G.; Westphalen, B.; Koeva-Balabanova, J.; Paradiso, A.; Maravic, Z.; Fotaki, V.; Malats, N.; Bernini, C.; Buglioni, S.; Kent, A.; Munzone, E.; Belina, I.; Van Meerbeeck, J.; Duffy, M.; Jagielska, B.; Capoluongo, E. Bringing Onco-innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Preprints 2020, 2020080393 Horgan, D.; Ciliberto, G.; Conte, P.; Curigliano, G.; Seijo, L.; M. Montuenga, L.; Garassino, M.; Penault-Llorca, F.; Galli, F.; Ray-Coquard, I.; Querleu, D.; Riegman, P.; Kerr, K.; Van Poppel, H.; Bjartell, A.; Codacci-Pisanelli, G.; Westphalen, B.; Koeva-Balabanova, J.; Paradiso, A.; Maravic, Z.; Fotaki, V.; Malats, N.; Bernini, C.; Buglioni, S.; Kent, A.; Munzone, E.; Belina, I.; Van Meerbeeck, J.; Duffy, M.; Jagielska, B.; Capoluongo, E. Bringing Onco-innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. Preprints 2020, 2020080393

Abstract

Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, pre-eminently in many cancers, but also in an ever-wider range of conditions – notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by country-related heterogeneity, data deficiencies, and lack of policy alignment on standards, approval – and the role of real-world evidence in the process - and reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europe's industrial competitiveness and innovation require an appropriate policy framework – starting with an update to outdated recommendations.

Subject Areas

cancer biomarkers; BRCA1/2; genomics; European recommendation

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.